Transgene's TG4050 heads toward first Phase II immune data in H2 2026
The readout will test whether the individualized cancer vaccine's Phase I immune responses and disease-free survival extend into the randomized Phase II population.
Executive Summary
- Transgene is set to report the first immune-response data from the randomized Phase II part of its individualized cancer vaccine trial in operable head and neck cancer, the step meant to show whether an earlier positive signal generalizes to a larger population.
- The bar this readout has to clear was set by the trial's own randomized Phase I part, which reported that every treated patient remained disease-free after roughly two and a half years of follow-up and that the vaccine produced durable, specific T-cell responses.
- The upcoming data measure immune response, not survival or recurrence, so the readout will inform confidence in the mechanism without itself establishing the efficacy outcome that a separate, later data point is designed to test.
- No other program in this cancer type shares TG4050's individualized neoantigen vaccine approach, leaving the readout without a direct precedent even as multiple immunotherapies advance in the same disease through later-phase trials.
The catalyst
Transgene said in a September 16, 2025 update that first immunogenicity data from the Phase II part of its ongoing Phase I/II trial of TG4050 (NCT04183166) would come in the second half of 2026, with efficacy data to follow in the fourth quarter of 2027. The trial is testing TG4050, an individualized neoantigen therapeutic vaccine built on Transgene's myvac platform, as adjuvant treatment after surgery in operable, HPV-negative head and neck squamous cell carcinoma. The primary outcome measure registered for the trial is disease-free survival. Transgene’s+1Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive ...Sep 16, 2025A Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166
What Phase I showed
The bar for the Phase II data comes from the trial's own randomized Phase I part. Transgene reported at ASCO 2025 that all patients who received TG4050 as a single agent remained disease-free for at least two years, with a median follow-up of 30 months, and that the vaccine induced durable, specific T-cell responses persisting 24 months after treatment start. Chairman and CEO Alessandro Riva said the company was "extremely proud that all patients treated with TG4050 in our Phase I trial remained disease-free after a median follow-up of 30 months" and called the results "a pivotal milestone" for the company's viral vector-based individualized vaccine platform. The company said the Phase I part met all trial endpoints, including safety and feasibility. Transgene’sTransgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive ...Sep 16, 2025
Trial history and timing
NCT04183166 has been active since December 2019 and is now Active, not recruiting, following completion of patient screening. The registered enrollment target grew from 30 to 80 patients in April 2024, and the primary completion date has moved twice, from November 2021 to November 2023 and then to December 2027, a cumulative shift of roughly six years since the trial's original registration. Those changes coincided with the trial's expansion into its randomized Phase II part, which is testing the vaccine in a larger population than the original Phase I cohort. NCT04183166A Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166
The competitive field
No program identified in this competitive field shares TG4050's individualized neoantigen vaccine mechanism in head and neck cancer, and the nearest analog, Scancell's Modi-1 vaccine, is being tested in a different cancer type and against a different target. The head and neck squamous cell carcinoma field itself is active, with PD-1 and PD-L1 checkpoint inhibitors, an antibody-drug conjugate, and other mechanisms advancing through Phase 3 testing from sponsors including Roche, AstraZeneca, GlaxoSmithKline, and EMD Serono. None of those programs use TG4050's vaccine platform, so this readout has no established mechanism-matched precedent to benchmark against; the closest comparison is the trial's own earlier-stage data.
What the readout will and will not settle
An immunogenicity readout from an 80-patient, non-registrational Phase I/II trial can show whether the T-cell responses observed in the smaller Phase I cohort persist at a comparable magnitude in the larger, randomized Phase II population. It is not designed to establish a survival or recurrence benefit; that comparison is reserved for the efficacy data Transgene has said it expects in the fourth quarter of 2027. Transgene has also said it is evaluating regulatory pathway options based on the Phase I data and any further immunological findings, but no designation or application has been recorded for TG4050. NCT04183166+1A Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive ...Sep 16, 2025
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.